Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...
Yahoo Finance

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full ...
The Manila Times

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

Monopar Therapeutics Inc. (Nasdaq: MNPR) ('Monopar” or the 'Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...
Business Insider

Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board

Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, ...
Yahoo Finance

Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board

LAUPHEIM, Germany and MILFORD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, ...

Inventiva to Participate in Four Upcoming March Investor Conferences

Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic ...
Agence France-Presse

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and ...